Monoamine oxidase — Drug Target

2 drugs 1 marketed 1 in Phase 3

All drugs that target Monoamine oxidase — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

Monoamine oxidase inhibitor · Monoamine oxidase inhibitor (MAOI)

Marketed (1)

Low dose oxelidine group · The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Monoamine oxidase inhibitor · Psychiatry/Neurology
Low-dose oxelidine acts as a monoamine oxidase inhibitor to increase neurotransmitter levels in the central nervous system.

Phase 3 pipeline (1)

FS MDPI · Teva Branded Pharmaceutical Products R&D, Inc. · Monoamine oxidase inhibitor (MAOI) · Psychiatry/Neurology
FS MDPI is a monoamine oxidase inhibitor that increases levels of dopamine, norepinephrine, and serotonin in the central nervous system.